The_DT
hematopoietic_JJ
transcription_NN
factor_NN
PU_NN
.1_CD
is_VBZ
downregulated_VBN
in_IN
human_JJ
multiple_JJ
myeloma_NN
cell_NN
lines_NNS
._.

PU_NN
.1_CD
is_VBZ
a_DT
hematopoietic_JJ
transcription_NN
factor_NN
belonging_VBG
to_TO
the_DT
Ets-family_NN
._.

It_PRP
is_VBZ
identical_JJ
to_TO
the_DT
Spi-1_NN
oncogene_NN
,_,
which_WDT
is_VBZ
implicated_VBN
in_IN
spleen_NN
focus-forming_JJ
virus-induced_JJ
murine_JJ
erythroleukemias_NNS
._.

PU_NN
.1_CD
seems_VBZ
to_TO
be_VB
required_VBN
for_IN
early_JJ
development_NN
of_IN
multiple_JJ
hematopoietic_JJ
lineages_NNS
,_,
but_CC
its_PRP$
expression_NN
in_IN
mature_JJ
cells_NNS
is_VBZ
preferentially_RB
observed_VBN
in_IN
cells_NNS
of_IN
the_DT
B-cell-and_NN
monocyte\/macrophage-differentiation_NN
lineage_NN
._.

It_PRP
binds_VBZ
the_DT
so-called_JJ
Pu_NN
box_NN
,_,
an_DT
important_JJ
tissue-specific_JJ
regulatory_JJ
DNA_NN
element_NN
present_JJ
in_IN
a_DT
number_NN
of_IN
genes_NNS
expressed_VBN
in_IN
these_DT
cell_NN
lineages_NNS
._.

We_PRP
have_VBP
analyzed_VBN
the_DT
expression_NN
and_CC
activity_NN
of_IN
PU_NN
.1_CD
during_IN
human_JJ
B-cell_NN
development_NN
using_VBG
a_DT
panel_NN
of_IN
B-cell_NN
lines_NNS
representing_VBG
different_JJ
stages_NNS
of_IN
maturation_NN
,_,
from_IN
early_JJ
precursors_NNS
to_TO
differentiated_VBN
plasma_NN
cells_NNS
._.

PU_NN
.1_CD
mRNA_NN
expression_NN
and_CC
PU_NN
.1_CD
DNA_NN
binding_NN
activity_NN
,_,
as_IN
measured_VBN
by_IN
Northern_NN
blot_NN
analysis_NN
and_CC
electrophoretic_JJ
mobility_NN
shift_NN
assay_NN
,_,
respectively_RB
,_,
were_VBD
evident_JJ
in_IN
cell_NN
lines_NNS
representing_VBG
pro-B_JJ
,_,
pre-B_JJ
,_,
and_CC
mature_JJ
B_NN
cells_NNS
._.

We_PRP
could_MD
also_RB
show_VB
Pu_NN
box-dependent_JJ
transactivation_NN
of_IN
a_DT
reporter_NN
gene_NN
in_IN
transient_JJ
transfections_NNS
in_IN
these_DT
cell_NN
lines_NNS
._.

In_IN
contrast_NN
,_,
in_IN
a_DT
number_NN
of_IN
multiple_JJ
myeloma_NN
cell_NN
lines_NNS
,_,
representing_VBG
differentiated_VBN
,_,
plasma_NN
cell-like_JJ
B_NN
cells_NNS
,_,
PU_NN
.1_CD
DNA_NN
binding_NN
activity_NN
,_,
mRNA_NN
expression_NN
,_,
and_CC
Pu_NN
box-dependent_JJ
transactivation_NN
were_VBD
absent_JJ
or_CC
detectable_JJ
at_IN
a_DT
very_RB
low_JJ
level_NN
._.

In_IN
lymphoblastoid_JJ
cell_NN
lines_NNS
,_,
which_WDT
exemplify_VBP
an_DT
intermediate_JJ
stage_NN
of_IN
B-cell_NN
differentiation_NN
,_,
a_DT
reduced_VBN
expression_NN
and_CC
activity_NN
were_VBD
observed_VBN
._.

The_DT
findings_NNS
in_IN
the_DT
human_JJ
multiple_JJ
myeloma_NN
cell_NN
lines_NNS
represent_VBP
the_DT
first_JJ
examples_NNS
of_IN
B_NN
cells_NNS
with_IN
downregulated_VBN
PU_NN
.1_CD
expression_NN
and_CC
apparently_RB
contradict_VBP
observations_NNS
in_IN
the_DT
murine_JJ
system_NN
in_IN
which_WDT
PU_NN
.1_CD
is_VBZ
expressed_VBN
and_CC
active_JJ
in_IN
plasmacytoma_NN
cell_NN
lines_NNS
._.

At_IN
present_JJ
,_,
it_PRP
is_VBZ
unclear_JJ
whether_IN
the_DT
lack_NN
of_IN
PU_NN
.1_CD
expression_NN
and_CC
activity_NN
in_IN
human_JJ
multiple_JJ
myeloma_NN
cell_NN
lines_NNS
represents_VBZ
a_DT
malignancy-associated_JJ
defect_NN
in_IN
these_DT
cells_NNS
or_CC
exemplifies_VBZ
a_DT
normal_JJ
developmental_JJ
regulation_NN
in_IN
terminally_RB
differentiated_VBN
B_NN
cells_NNS
._.

